Amgen vs Neurocrine Biosciences
Amgen (AMGN) and Neurocrine Biosciences (NBIX) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $236B
- Last close
- $435.64
- 12 months
- +29.6%
- Market value
- $15.2B
- Last close
- $150.57
- 12 months
- +8.3%
At a glance
- By market value, Amgen ($235.6B) is about 15 times Neurocrine Biosciences ($15.2B).
- Over the last 12 months Amgen's share price moved +29.6% and Neurocrine Biosciences's +8.3%; against the S&P 500 that is +23.9 points and +2.6 points.
- In their last fiscal years Amgen kept 21.0% of revenue as net income and Neurocrine Biosciences 16.7%.
- In the last 90 days insiders reported 0 open-market purchases at Amgen and 0 at Neurocrine Biosciences; members of Congress disclosed 6 trades in Amgen and 0 in Neurocrine Biosciences.
- Next results: Amgen Feb 1, 2027, Neurocrine Biosciences Feb 9, 2027.
Share prices on one chart
Amgen and Neurocrine Biosciences, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Amgen AMGNNASDAQ · Biotechnology | Neurocrine Biosciences NBIXNASDAQ · Biotechnology | |
|---|---|---|
| Size and profitability | ||
| Market value | $236B | $15.2B |
| Revenue, last fiscal year | $36.8B | $2.86B |
| Net income, last fiscal year | $7.71B | $479M |
| Net marginNet income as a share of revenue | 21.0% | 16.7% |
| Free cash flow | $8.1B | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Amgen against
Common questions
How is Amgen different from Neurocrine Biosciences?
Amgen (AMGN) is in Biotechnology on NASDAQ, with $36.8B of revenue in its last fiscal year and a net margin of 21.0%. Neurocrine Biosciences (NBIX) is in Biotechnology on NASDAQ, with $2.86B of revenue in its last fiscal year and a net margin of 16.7%. Both are in the same industry, so the gap is mostly one of size and profitability. The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Amgen and Neurocrine Biosciences compare in size?
Amgen has the larger market value: Amgen $236B and Neurocrine Biosciences $15.2B, at the last close.
Whose share price rose more over the last 12 months, AMGN or NBIX?
Over the last 12 months Amgen moved +29.6% and Neurocrine Biosciences +8.3%. Past price moves say nothing about the future.
Which has had more insider buying, Amgen or Neurocrine Biosciences?
Since 2006, Neurocrine Biosciences insiders reported 106 open-market purchases against 9 for Amgen. These are counts of what was filed, not a view on either stock.
Do members of Congress trade AMGN or NBIX?
In the last 12 months, members of Congress disclosed 17 trades in Amgen (AMGN) and 0 in Neurocrine Biosciences (NBIX).
When did insiders last buy AMGN and NBIX?
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Amgen pageNeurocrine Biosciences pageRare insider trades this weekAll comparisons
https://oqro.io/compare/amgn-vs-nbix







